San Francisco – February 17, 2017 – Cooley advised Rigel Pharmaceuticals on its $46 million shelf-takedown offering of 23,000,000 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares.
Jefferies, Piper Jaffray & Co. and BMO Capital Markets acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.
Rigel, which trades on the NASDAQ Global Select Market as "RIGL," is a clinical-stage biotech company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Its pioneering research focuses on signaling pathways that are critical to disease mechanisms.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.